Adenosine is released by skeletal and cardiac muscles when their metabolism increases: it serves to couple O 2 supply with O 2 demand by causing vasodilatation. This review argues that adenosine plays a similar role in skeletal muscle in systemic hypoxia. It accounts for »50% of the increase in muscle vascular conductance and, within muscle, it causes dilatation of individual arterioles, thus maximizing the distribution of O 2 and allowing O 2 consumption to remain constant when O 2 delivery is reduced. In vivo and in vitro studies have indicated that adenosine can induce dilatation in several different ways. This review argues that during systemic hypoxia, adenosine is predominantly released from the endothelium and acts on endothelial A 1 receptors to produce dilatation in a nitric oxide (NO)-dependent manner. A 1 receptor stimulation increases the synthesis of NO by a process initiated by opening of ATP-sensitive K + (K ATP ) channels. Moreover, recent ®ndings suggest that prostaglandins also make a major contribution to the hypoxia-induced dilatation, but that the dilator pathways for adenosine, NO and prostaglandins are interdependent. In addition, adenosine released from the skeletal muscle ®bres contributes indirectly to the dilatation by stimulating A 1 and A 2 receptors on the muscle ®bres, opening K ATP channels and allowing ef¯ux of K + , which is a vasodilator. Finally, by acting on endothelial A 1 receptors, adenosine attenuates the vasoconstrictor effects of constant or bursting patterns of sympathetic activity. This limits the extent to which the sympathetic nervous system can reduce O 2 delivery to muscle when it is already compromized by systemic hypoxia.
It is generally accepted that systemic hypoxia causes vasodilatation in skeletal muscle. However, the mechanisms underlying this response have not been clear. A widespread assumption, manifest in many textbooks of physiology, is that the muscle vasodilatation of systemic hypoxia is comparable with the muscle vasodilatation that is associated with muscle contraction: functional hyperaemia. Both are used as examples of metabolic coupling in that the vasodilatation enables O 2 supply to be coupled to O 2 demand. According to this metabolic hypothesis, the vasodilatation can be attributed to metabolic factors that are released from the blood vessel wall or skeletal muscle ®bres when there is a mismatch between O 2 supply and O 2 demand. The idea that a relative lack of O 2 might have a direct relaxing effect on the vascular smooth muscle became less popular following the demonstration that hypoxia did not relax pig carotid artery in vitro unless the core of the blood vessel wall was virtually anoxic (Pittman & Duling 1973) . On the other hand, attention was naturally directed towards the skeletal muscle ®bres as the source of the metabolites because it is known that during contraction they release a number of substances, including adenosine, K + and H + , which are vasodilators. However, over the last 15 years or so, it has become increasingly clear that moderate levels of hypoxia can have a pronounced dilator effect on the feed arteries and arterioles of skeletal muscle and other tissues. Hypoxia over the range of PO 2 values found in the blood during systemic hypoxia can release substances from the endothelium which then dilate the underlying smooth muscle (e.g. Fredricks et al. 1994) , or act more directly on the smooth muscle to affect the ion channels and second messenger systems that govern vascular tone (e.g. Franco-Obregon & Lopez-Barneo 1996) . It may also be noted that although the dilator responses of systemic hypoxia and muscle contraction have been considered together, they are in fact, very different. In systemic hypoxia, the fundamental problem is a decrease in the O 2 supply because the PO 2 of the blood perfusing the blood vessels falls, whereas during muscle contraction, it is the O 2 demand that increases because the O 2 consumption of the muscle ®bres is increased. In retrospect, it is perhaps not surprising that the experimental evidence we have been accumulating suggests the muscle vasodilatation of systemic hypoxia is largely attributable to the actions of substances that are released from the endothelium, particularly to adenosine.
Adenosine itself has attracted a great deal of interest over recent years. It is known to originate directly or indirectly from many different cell types under hypoxic conditions. Further, it has been established from studies that have largely been performed in vitro, that it has the potential to produce dilatation in a variety of ways: by acting on several different subtypes of adenosine receptor on the endothelium or vascular smooth muscle, and by acting on adenosine receptors on other cell types so as to cause a secondary dilator action. This review considers the evidence that adenosine is largely released from the endothelium in systemic hypoxia and the experiments we have designed speci®cally to establish the receptor subtypes and cellular mechanisms through which it may act in skeletal muscle during systemic hypoxia. Emphasis is placed on the endothelium as a source and site of action of adenosine. However, attention is also given to our evidence that some of the adenosine may be released from and act upon adenosine receptors on the skeletal muscle ®bres and to our recent ®ndings that adenosine can act preand post-synaptically, to modulate the constrictor effects of the increase in sympathetic activity that occurs during systemic hypoxia. These mechanisms probably do no more than facilitate the dilator in¯u-ence adenosine has by acting on the endothelium.
METHODS
The great majority of experiments discussed below were performed on anaesthetized rats, prepared for the recording of arterial blood pressure, heart rate, and in some cases, respiratory minute volume and respiratory frequency. In some series of experiments the femoral artery was prepared to allow the recording of blood ow to hindlimb muscle by using an electromagnetic or transonic¯ow meter. In these experiments, femoral vascular conductance (FVC) was calculated by dividing femoral blood¯ow by arterial pressure or femoral vascular resistance (FVR) was calculated as arterial pressure divided by femoral blood¯ow. In other series of experiments, the spinotrapezius muscle was prepared for intravital microscopy. In these experiments, changes in the diameter of individual arterioles and venules were measured by analysis of video recordings. In all experiments, acute systemic hypoxia was achieved by giving the animal a hypoxic mixture (usually 8% O 2 in N 2 ) to breathe for 3 or 5 min. In the experiments in which FVC or FVR was recorded, pharmacological antagonists were given intravenously, while agonists were generally given intra-arterially directly into the femoral artery, via a cannula placed retrogradely in the ventral tail artery. In the experiments in which intravital microscopy was used, pharmacological antagonists and agonists were generally applied topically to the spinotrapezius muscle: this meant that they had no detectable effect upon the baselines of systemic variables or upon evoked changes in systemic variables. The techniques and equipment used for these experiments are described in our recent publications (see Mian & Marshall 1991c , Bryan & Marshall 1999a and references therein). All experiments performed by the author and colleagues were carried out according to the requirements of the Home Of®ce Animals (Scienti®c Procedures) Act 1986 of the UK.
Nature of the muscle vascular response to systemic hypoxia
It is clear from experiments performed on human subjects and on the rat, that the muscle vasodilatation evoked by systemic hypoxia persists, or is even enhanced, after pharmacological blockade of the vasoconstrictor in¯uences of the sympathetic nerve ®bres (Black & Roddie 1958 , Marshall & Metcalfe 1988 . Indeed, it is known that stimulation of peripheral chemoreceptors evokes an increase in sympathetic activity to skeletal muscle (Marshall 1994) , and there is evidence that systemic hypoxia increases the sympathetic vasoconstrictor nerve activity to skeletal muscle (for further discussion see below). As any muscle vasodilatation that occurs secondary to hypoxia-induced hyperventilation is small in both humans and rats (see Marshall 1994) , it is reasonable to propose that the hypoxia-induced increase in muscle vascular conductance is mediated by local dilator factors that act upon the blood vessels and by the ability of such factors to interfere with the constrictor in¯uences of the sympathetic nerve ®bres.
Experiments on the rat have shown that the magnitude of increase in FVC is graded with the level of systemic hypoxia, suggesting that the dilator factor(s) are produced and act in proportion to the level of hypoxia (Marshall & Metcalfe 1988) . On the other hand, there is considerable heterogeneity in the way individual arterioles and venules respond within a single muscle to a given level of systemic hypoxia: many vessels dilate, but others constrict and there are qualitative differences in the sizes of the constrictor and dilator responses (Mian & Marshall 1991a, see Fig. 1 ). It is likely that the constrictor responses re¯ect the in¯uence of the sympathetic nerve ®bres and of circulating constrictor hormones such as catecholamines ( Fig. 1 ) and vasopressin (Marshall 1982 , Mian & Marshall 1991a Marshall et al. 1993a) and that the extent to which these are overwhelmed by local dilator in¯uences varies in different regions of the muscle depending upon the severity of the local level of hypoxia. Regional variations in the partial pressure of O 2 in tissue (tpO 2 ) at a given level of systemic arterial pO 2 (P a O 2 ) can be attributed to such factors as the distance travelled by the blood from the main feeding artery to the recording site, given that O 2 diffuses through the vessel walls along the length of the vascular tree, on the proximity of arterioles and venules, given that O 2 can short circuit from one to another, and on variations in the O 2 consumption of nearby skeletal muscle ®bres (see Marshall 1995) . From measurements of tpO 2 within skeletal muscle, it seems that mean tpO 2 is reduced in systemic hypoxia in a predictable way, but that concomitantly, the heterogeneity of tpO 2 in different regions of muscle becomes less pronounced (Harrison et al. 1990 ). This would be readily explained if arteriolar dilatation is most pronounced in regions of the muscle where hypoxia is most severe. Moreover, if this improves the distribution of O 2 within the muscle, it would, in turn, explain how muscle O 2 consumption can remain constant even when gross O 2 delivery in the arterial blood is greatly compromized (Marshall & Davies 1999; Edmunds & Marshall 2000) . These considerations lead one to the view that the factor(s) responsible for hypoxia-induced dilatation are under localized and precise control and that they are produced by, or close to, individual blood vessels in an O 2 -dependent manner.
A role for adenosine
It is well known that adenosine is released by hypoxic tissues. Speci®cally, it is released by skeletal muscle Figure 1 The in¯uences of the sympathetic ®bres and of locally released adenosine on the arterioles of skeletal muscle during systemic hypoxia. The schematic diagram shows the relationship of the sympathetic noradrenergic nerve ®bres to the arterial vessels of the spinotrapezius muscle. There is a network of ®bres around the main arteries, primary and secondary arterioles (MA, 1°A and 2°A, respectively) which follows the terminal arterioles (TA) before branching out into the surrounding tissue (modi®ed from Marshall 1982) . The bar charts to the right show the effects of the a-adrenoreceptor antagonist, phentolamine (below) and the adenosine receptor antagonist 8-phenyltheophylline (above) on changes in diameter evoked in individual arterioles by systemic hypoxia (breathing 6% O 2 , modi®ed from Mian & Marshall 1991b, c) . The columns show the mean (SEM)% change in diameter before and after the antagonist (open and shaded columns, respectively); the numbers in parentheses indicate the number of arterioles). ** P < 0.01, *P 0.05, respectively, before vs. after antagonist. Blockade of a-adrenoreceptors accentuates dilator responses and reverses constrictor responses to dilator responses particularly in the 1°and 2°arterioles, the vessels that constrict most when the sympathetic ®bres are directly stimulated. By contrast, blockade of adenosine receptors reduces dilator responses or reverses dilator responses to constrictor responses, particularly in 2°and terminal arterioles, the vessels that are known to be most sensitive to locally released metabolites.
under conditions in which O 2 demand begins to exceed the existing O 2 supply, for example, during muscle contraction, and there is much evidence that adenosine is a potent vasodilator in skeletal muscle. Thus, adenosine is an obvious, strong candidate for the muscle vasodilatation of systemic hypoxia. In fact, the increase in FVC evoked by systemic hypoxia can be reduced by »50% by the adenosine receptor antagonists 8-phenyl theophylline (8-PT) and 8-sulphophenyl theophylline (8-SPT) and by adenosine deaminase (Neylon & Marshall 1991 , Thomas et al. 1994 . Similarly, topical application of 8-PT to the spinotrapezus muscle greatly reduced arteriolar dilator responses evoked by systemic hypoxia or converted them to constrictor responses and it potentiated arteriolar constrictor responses (Fig. 1) , as would be expected if it removed the dilator in¯uence of adenosine. Further, the vessels that were most affected by 8-PT were the more distal arteriolar vessels, the secondary and terminal arterioles (Fig. 1) . These are the sites along the arterial tree where the level of hypoxia would be expected to be most severe and are consistent with adenosine being released in proportion to the level of hypoxia (Mian & Marshall 1991c) .
Possible sites of production and action of adenosine
Adenosine can be produced intracellularly by S-adenosyl-L-homocysteine and by the action of cytosolic 5¢ nucleotidase on AMP or extracellularly by 5¢ ectonucleotidase which is bound to cell membranes. Within skeletal muscle, adenosine is produced predominantly by 5¢ nucleotidase. The great majority of this enzyme is localized to the sarcolemma of the skeletal muscle ®bres adjacent to the blood vessels and to the endothelium, such that there is a gradient from the highest concentrations in the most distal vessels and to lowest concentrations in the more proximal vessels. There is little or no 5¢ nucleotidase in the vascular smooth muscle (Rubio et al. 1973) .
For skeletal muscle during muscle contraction, the evidence suggests that adenosine is predominantly released from skeletal muscle ®bres and that more is released from oxidative than from glycolytic ®bres (Bockman & McKenzie 1983) . By contrast, our evidence suggests that during systemic hypoxia adenosine is mainly released from the endothelium. Thus, in the spinotrapezus muscle, individual arterioles generally run transversely or obliquely across many different muscle ®bres and the spinotrapezus as a whole is composed of approximately equal proportions of oxidative, glycolytic and mixed oxidative/glycolytic ®bres which are randomly distributed: there is no correlation between the position of arterioles that dilate or constrict in systemic hypoxia and the position or type of muscle ®bre they cross (Mian & Marshall 1991c) . Further, systemic hypoxia evokes dilatation that is mainly mediated by adenosine in the arterioles of the intestinal mesentery although there is virtually no tissue parenchyma around these blood vessels (Mian & Marshall 1995) . Support for the endothelium as the source of adenosine in hypoxia is provided by the evidence that adenosine was released from coronary endothelium in vivo by hypoxic perfusion (Deussen et al. 1986 ) and from endothelial cells in vitro when the pO 2 of the bathing medium was reduced (Nees & Gerlach 1983) . A difference between the major sources of adenosine in muscle contraction and systemic hypoxia would not be surprising. For, during muscle contraction with normal P a O 2 , a decrease in pO 2 is likely to occur ®rst in the muscle ®bres when their O 2 consumption increases. By contrast, in systemic hypoxia when muscle ®bres are at rest, the decrease in pO 2 is likely to occur earlier and most markedly in the adluminal surface of the endothelium. Indeed, any vasodilatation that is initiated by the fall in endothelial pO 2 as a consequence of the fall in P a O 2 , would help to ameliorate the fall in muscle ®bre pO 2 .
The suggestion that the adenosine of systemic hypoxia mainly originates from the endothelium does not, of course, exclude the possibility that it is actually ATP that is released and that adenosine is formed extracellularly by the action of 5¢ ectonucleotidase. Certainly, in vitro, hypoxic perfusion of coronary circulation was shown to release ATP as well as adenosine (Lincoln et al. 1991) . In our own experiments, ab methylene ADP (AOPCP) which inhibits the action of 5¢ nucleotidase had no signi®cant effect on the muscle vasodilatation of systemic hypoxia. However, this result was inconclusive because AOPCP binds so avidly to plasma proteins that the free concentration of AOPCP may not have been suf®ciently high (Skinner & Marshall 1996 4 ) . It is also possible that some of the adenosine that is important in systemic hypoxia is released from the muscle ®bres. Moreover, given that sympathetic noradrenerigic ®bres contain ATP and that ATP which is co-released with noradrenaline, can be degraded by 5¢ ectonucleotidase (Kennedy et al. 1986 , Cunnane & Manchanda 1998 , adenosine may originate as an indirect consequence of an increase in sympathetic nerve activity. These possibilities are given further consideration below. Adenosine may also originate from the ATP that is released by circulating red blood cells when they become hypoxic (see Ellsworth et al. 1995 and this volume) . The physiological signi®cance of ATP or adenosine that is released by red blood cells during systemic hypoxia is dif®cult to investigate and has not been studied to date.
As far as the sites of action of adenosine are concerned, the endothelium has an avid uptake mechanism for adenosine (Olsson & Pearson 1990) . Thus, any adenosine that is released from endothelial cells seems most likely to act on adenosine receptors upon the endothelial cells although, if it is released from the abluminal surface of the endothelium, it may act on the vascular smooth muscle as well. Any adenosine that is released from skeletal muscle ®bres or sympathetic nerve ®bres is most likely to act upon receptors on the vascular smooth muscle, on the skeletal muscle ®bres, or prejunctionally on the sympathetic varicosities. Potentially, stimulation of adenosine receptors at each of these sites can induce dilatation or can modify dilatation or constriction produced by some other factor, by a number of known mechanisms (see Fig. 2 ). The discussion that follows concerns the studies that have allowed us to build up a picture of which of these mechanisms is important in systemic hypoxia.
Mechanisms of vasodilatation
Adenosine receptor subtypes Adenosine can act by at least three major types of receptors (A 1 , A 2 and A 3 ) the A 2 receptor being divided into two subtypes (A 2A and A 2B , Tucker & Linden 1993) . For many years it was accepted that vasodilatation is produced by A 2 receptor stimulation via an increase in intracellular cAMP and the more recent literature suggests the A 2A receptors are of greater functional importance than the A 2B receptors (Olsson & Pearson 1990 , Tucker & Linden 1993 . However, whilst the older literature indicated that A 1 receptor stimulation leads to a reduction in cAMP levels and to vasoconstriction, at least in some tissues (Olsson & Pearson 1990) , several recent studies have shown that A 1 receptor stimulation can evoke dilatation, for example of coronary arteries and arterioles (Merkel et al. 1992 , Nakhostine & Lamontagne 1993 and diaphragm arterioles (Danialou et al. 1997) . In view of this, we have tested the roles of A 1 as well as of A 2A receptors in skeletal muscle vasculature.
Both the infusion of a selective A 1 receptor agonist and of a selective A 2A receptor agonist were able to evoke a substantial increase in FVC, equivalent in magnitude to the increase in FVC evoked by systemic hypoxia. These agonist-induced responses were blocked by an appropriate dose of the A 1 or A 2A receptor antagonist (DPCPX and ZM 241385, respectively) , and each of the antagonists reduced the increase in FVC evoked by infusion of adenosine by »50% (Bryan & Marshall 1999a ). In addition, DPCPX reduced the hypoxia-induced increase in FVC by »50% (Fig. 3) . This is equivalent to the inhibition produced by the adenosine receptor antagonist, 8-PT, which is non-selective between receptor subtypes. By contrast, ZM 241385 had no detectable effect upon the hypoxiainduced increase in FVC (Bryan & Marshall 1999a , see Fig. 3 ). These results strongly suggest that both A 1 and A 2A receptors are present within skeletal muscle and can evoke vasodilatation when stimulated, but that A 1 receptors alone are responsible for the component of the muscle vasodilatation of systemic hypoxia that is attributable to adenosine.
This proposal not only contrasts with the older literature indicating that dilatation is mediated by A 2A receptors (see above) but it contrasts with the recent ®nding that the adenosine-dependent component of dilatation that occurs during muscle contraction is mediated by A 2A receptors (Poucher 1996) . Such a disparity could arise if the A 1 receptors are predominantly on the endothelium and the A 2A receptors are predominantly on the vascular smooth muscle, if, as argued above, the adenosine released in systemic hyp- Adenosine may be released from the skeletal muscle ®bres (1) and act on adenosine receptors (Ad) on the skeletal muscle ®bres that are coupled to ATP-sensitive K + channels (K ATP ): through these K + may be released and act on the vascular smooth muscle to cause vasodilatation (±). Adenosine may also be released from the endothelium and act on Ad on the vascular smooth muscle to open K ATP , cause K + ef¯ux and membrane hyperpolarization (2) or increase intracellular cAMP (3) and thereby, vasodilatation. Adenosine that is generated from ATP released from sympathetic nerve varicosities, and adenosine or K + released from skeletal muscle ®bres may act presynaptically on Ad to modulate release of noradrenaline (4). Further, adenosine released from the endothelium may act on endothelial Ad to generate NO (5) which causes dilatation. In addition, adrenaline arriving in the plasma may not only stimulate b 2 receptors on the vascular smooth muscle to cause dilatation, but can regulate interstitial concentration of K + by stimulating b 2 receptors on skeletal muscle ®bres which stimulate the Na + /K + pump.
Ó 2000 Scandinavian Physiological Society oxia mainly originates from the endothelium while that released during muscle contraction mainly comes from the muscle ®bres. It may be noted that adenosine has an »80-fold greater potency for A 1 than for A 2A receptors (Ueeda et al. 1991) . This should allow adenosine to be particularly effective in producing vasodilatation via A 1 receptors, when the local level of O 2 falls in the vicinity of the endothelium.
The endothelium and nitric oxide Although adenosine was considered to be an endothelium-independent vasodilator for many years, it has become increasingly obvious that it can act via the endothelium, in an endothelium-, and more speci®cally, in a NO-dependent manner. Thus, it was very reasonable to question whether the muscle vasodilatation of systemic hypoxia is NO-dependent. Our ®rst evidence that this might be so came when we used the NO synthesis inhibitor L-NAME (nitro-L-arginine methyl ester). Systemic administration of L-NAME not only produced the expected decrease in baseline FVC, indicating removal of a tonic vasodilator in¯uence of NO, but greatly reduced the increase in FVC evoked by systemic hypoxia and a comparable increase in FVC evoked by infusion of adenosine (Skinner & Marshall 1996) . Subsequently, we showed that although L-NAME decreased baseline FVC, it had no effect on the increase in FVC evoked by infusion of the NO donor, SNP (sodium nitroprusside; Bryan & Marshall 1999b ). Further, L-NAME had no effect on baseline arteriolar diameter in the spinotrapezius muscle, but greatly reduced the mean increase in arteriolar diameter evoked by systemic hypoxia (T. Butler & J.M. Marshall unpublished observations).
It might be argued that L-NAME achieved these effects by reducing tonic levels of NO and thereby cGMP, the second messenger for NO, hence attenuating the known synergism between cGAMP and cAMP in mediating vasodilatation (De Wit et al. 1994) . This may be a contributing factor, but it is unlikely to be the full explanation. Firstly, Baker & Sutton (1993) showed that dilatation evoked in skeletal muscle arterioles by intra-arterial infusion of adenosine was virtually abolished by L-NAME, whereas that evoked by topical application of adenosine persisted. This clearly demonstrated that adenosine can still induce dilatation when NO synthesis is blocked and suggested that it is the route of access of adenosine that determines whether it acts in a NO-dependent or NO-independent manner. Secondly, it has been shown that adenosine can produce an increase in cGMP levels in HUVEC (human umbilical vein endothelial cells) which can be blocked by L-NAME or by adenosine receptor antagonists (Sobrevia et al. 1997) . In accord with this, we have recently shown by using a NO electrode, that adenosine can evoke an increase in NO signal that can be reduced or abolished by 8-SPT (Rolleston & Marshall 2000) . Thus, we have proposed that adenosine that is released from the endothelium during systemic hypoxia acts back on adenosine receptors on the endothelium to increase the synthesis of NO which then causes dilatation by acting on the vascular smooth muscle (see Bryan & Marshall 1999a, b) .
The question then arises as to whether the adenosine receptors on the endothelium are of the A 1 or A 2A subtype. In fact, L-NAME reduced the increase in FVC evoked by a speci®c A 2A receptor agonist by 60±70%, suggesting that A 2A receptors can produce both NOdependent and NO-independent dilatation (Bryan & Marshall 1999b) . This is consistent with the evidence discussed above that A 2 receptor stimulation increases cAMP in vascular smooth muscle, with the observation that the increase in cGMP that is evoked in HUVEC by adenosine is mediated by A 2A receptors (Sobrevia et al. 1997 ) and with our own evidence that the adenosineevoked increase in NO release from HUVEC can be attenuated by ZM 241385 (Rolleston & Marshall 2000) .
On the other hand, the increase in FVC evoked by the selective A 1 receptor agonist was totally abolished by L-NAME. Similarly, Danialou et al. (1997) showed that dilatation evoked in diaphragm arterioles by an A 1 agonist was attenuated by NO synthesis inhibition. Although Sobrevia et al. (1997) reported that the increase in cGMP evoked in HUVEC by adenosine was unaffected by DPCPX, we recently found that the increase in NO signal evoked by adenosine HUVEC was attenuated by DPCPX (Rolleston & Marshall 2000) . This discrepancy may be explained if A 1 receptor stimulation does not generate suf®cient cGMP for it to be measured at the end of a 2-min stimulation period. Certainly, there is recent evidence that endothelial cells do express A 1 receptors (Hellsten & Radegran, this volume). Thus, in view of our ®nding that the vasodilatation evoked by systemic hypoxia is mediated by A 1 receptors and that it is largely NO dependent, we propose that it is the A 1 receptors on the endothelium that are functionally important in producing vasodilatation in systemic hypoxia (Bryan & Marshall 1999b ).
ATP-sensitive K
+ (K ATP ) channels The K ATP channels were identi®ed as ones that are kept closed by high levels of intracellular ATP, but are opened and allow K + ef¯ux, when intracellular ATP levels fall. It is now clear that their open±close state is not simply determined by ATP concentration. In particular, they may be coupled to several different receptors, including adenosine receptors, in such a way that adenosine receptor stimulation can activate the channel (Quayle & Standen 1994) . As K ATP channels are present on many of the cell types within skeletal muscle, and because there are several different ways in which they may cause dilatation, it is an interesting question as to how they may be involved in the vasodilatation of systemic hypoxia.
In 1993, we showed that the early part (®rst-min) of the increase in FVC evoked by systemic hypoxia was greatly reduced by glibenclamide, which inhibits K ATP channels (Marshall et al. 1993b 5 ), thus implicating these channels at least in the initiation of the dilatation. (Mian et al. 1990 , Marshall et al. 1993b . We also found that this hypoxia-induced increase in [K + ] v was abolished by glibenclamide and by the adenosine receptor antagonist 8-PT which concomitantly reduced both the early and late phases of the muscle vasodilatation, as we had shown before. Furthermore, adenosine infusion produced an increase in [K + ] v as well as the expected increase in FVC and both were attenuated by 8-PT (Marshall et al. 1993b) .
We accepted that the interpretation of these results was complex for we had only obtained`instantaneous' measurements of K + in arterial and venous plasma from single samples taken in normoxia and at certain times in hypoxia. Further, in addition to any role K ATP channels might play in determining K + ef¯ux from skeletal muscle, there are Na + /K + pumps on skeletal muscle ®bres whose stimulation can increase K + uptake (Clausen 1986). Indeed, we had already provided evidence that during systemic hypoxia, stimulation of b adrenoreceptors that are coupled to the Na + /K + pump can limit the increase in [K + ] v by increasing K + uptake (Mian et al. 1990 ). Nevertheless, given that glibenclamide and 8-PT had no effect on the hypoxia-induced increase in [K + ] a , we proposed that the most likely explanation for their ability to prevent the hypoxiainduced increase in [K + ] v was that they had blocked an ef¯ux of K + from muscle: there was no obvious mechanism by which they might increase uptake of K + . Further, as the effect on [K + ] v was to reduce it by as much as 0.5 mM, we proposed that this was too large to be accounted for by an effect on¯ux across cells of the blood vessels, but largely re¯ected a decrease in the ef¯ux from skeletal muscle ®bres. Thus, putting our results together at this stage, we suggested that adenosine released during systemic hypoxia stimulates adenosine receptors on skeletal muscle ®bres that are coupled to K ATP channels causing K + ef¯ux (Marshall et al. 1993a) . Because the endothelium acts as an effective metabolic barrier to the movement of adenosine generated by the endothelium (see above), we surmized that the adenosine that acts on the skeletal muscle ®bres probably originates from those ®bres (see Fig. 4 ). Given that K + is a recognized vasodilator whose in¯uences are potentiated by hypoxia (Skinner & Powell 1967) , we proposed that K + released from the muscle ®bres contributes to dilatation of systemic hypoxia by acting on the vascular smooth muscle (Marshall et al. 1993b) .
The results we have obtained more recently suggest that we had over-estimated the importance of K + released from the K ATP channels on skeletal muscle ®bres but we still have reasons to believe these channels play a key role in systemic hypoxia. In recent experiments, in contrast to our earlier studies, we took steps to vascularly isolate the drainage of the muscles of the hindlimb so that we were more con®dent that the venous samples re¯ected blood drained from skeletal muscle only and could calculate venous±arterial differences for [K + ] v±a across muscle. Given the relatively small blood volume of the rat, we were still restricted to samples taken in normoxia and at one time in hypoxia, at the ®fth minute.
Using these methods, we found that systemic hypoxia did not have a predictable effect on [K + ] v±a ; in some experiments there was net uptake, in others net release, at least at the ®fth minute of hypoxia. However, both the A 1 receptor antagonist DPCPX and the A 2A receptor antagonist ZM 241385 caused a small but signi®cant decrease in [K + ] v±a in hypoxia, suggesting that adenosine may stimulate both A 1 and A 2A receptors in the skeletal muscle ®bres to facilitate K + ef¯ux (Bryan & Marshall 1999a , Fig. 4) . Accordingly, there is electrophysiological evidence that A 1 receptors are coupled to K ATP channels on rat skeletal muscle ®bres (Barrett-Jolley et al. 1996 6 ). Whether A 2A receptors may be similarly coupled to skeletal muscle K ATP channels has not been investigated.
However, as indicated above, whereas DPCPX reduced the hypoxia-induced dilatation, ZM 243185 had no such effect. Moreover, when given as an infusion, neither the selective A 1 agonist, nor the selective A 2A receptor agonist affected [K + ] v±a at the ®fth minute of infusion, although they both caused substantial dilatation at this time (Bryan & Marshall 1999a) . And yet, both the increase in FVC evoked by the A 1 agonist, and that evoked by the A 2A agonist were greatly reduced by Figure 4 Schematic diagram showing proposed sources, sites and mechanisms of action of adenosine in skeletal muscle during systemic hypoxia. Systemic hypoxia causes release of adenosine from endothelium which stimulates A 1 receptors on endothelial cells that are coupled to ATP-sensitive K + channels (K ATP ), thereby increasing the synthesis of nitric oxide (NO) which acts on the vascular smooth muscle to induce vasodilatation. Hypoxia may also release adenosine from the skeletal muscle ®bres which stimulates A 1 and A 2 receptors on the skeletal muscle ®bres that are coupled to K ATP , causing an ef¯ux of K + , which makes a small contribution to the vasodilatation by relaxing the vascular smooth muscle. In addition, adenosine that originates from the ATP released by sympathetic varicosities may act presynaptically on A 1 receptors to facilitate noradrenaline release and sympathetically mediated vasoconstriction. However, the constrictor action of noradrenaline can be largely overcome by the dilator in¯uence of adenosine acting on endothelial A 1 receptors.
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Adenosine and muscle vasodilatation in acute systemic hypoxia I Á J M Marshall glibenclamide (Bryan & Marshall 1999b ). As we could so readily dissociate effects on [K + ] v±a from effects on FVC, it seems that any contribution made by K + released via K ATP from skeletal muscle ®bres to the dilatation of systemic hypoxia, whether stimulated by A 1 or A 2A receptors, must be very small. Rather, the ®ndings that the increases in FVC evoked by systemic hypoxia, by adenosine and by A 1 and A 2 receptor agonists were all sensitive to glibenclamide suggests that K ATP channels on the endothelium or vascular smooth muscle play fundamental roles in their mediation (Bryan & Marshall 1999a, b) .
In these same studies, we found that the increase in FVC evoked by the NO donor SNP was not affected by glibenclamide (Bryan & Marshall 1999b) . Thus, the ability of NO to cause dilatation by opening K ATP channels on vascular smooth muscle (Murphy & Braden 1995 7 ) does not seem to be functionally important in skeletal muscle vasculature. Rather, as our evidence already suggested that the vasodilatation of systemic hypoxia is mainly mediated by adenosine released from the endothelial cells and acting on A 1 receptors on the endothelial cells, we proposed that these are coupled to K ATP channels (see Fig. 4 ). This is consistent with direct evidence that endothelial cells have K ATP channels (Janigro et al. 1993 , Langeinrich & Daut 1997 ) and with observations that adenosine increases cGMP in HUVEC by inducing hyperpolarization (Sobrevia et al. 1997) . We must acknowledge that it was predominantly the early part of the hypoxia-induced muscle dilatation that was sensitive to glibenclamide (see above). Thus, we have suggested that when K ATP channels are inhibited, adenosine may induce dilatation by another mechanism, maybe by opening Ca 2+ -activated K + channels (see Mehrke & Daut 1990) . We cannot exclude a functional role for K ATP channels on the vascular smooth muscle that are coupled to A 1 receptors (Dart & Standen 1993) and stimulated by adenosine released from the abluminal surface of the endothelial cells, but our results do not require this mechanism.
Adenosine and prostaglandins
It has been clear from our studies that whatever antagonist we use to inhibit the action of adenosine, we cannot block more than »50% of the muscle vasodilator response evoked by systemic hypoxia. This suggests that at least one more factor is involved. There is evidence that during hypoxic perfusion in vitro, newly synthesized prostaglandins are released from the endothelium of arteries and arterioles taken from skeletal muscle and that they contribute to the hypoxic dilatation (Busse et al. 1984 , Messina et al. 1992 . There is also evidence that prostaglandins contribute to hypoxiainduced dilatation in the coronary circulation of whole hearts in vitro (Nakhostine & Lamontagne 1994). Thus, we have recently begun to investigate the possible contribution of prostaglandins to dilatation evoked in skeletal muscle by systemic hypoxia. We found that the prostaglandin synthesis inhibitor, diclofenac, had no effect on baseline FVC, but reduced the increase in FVC evoked by systemic hypoxia by 50± 60%. However, diclofenac had no effect on an increase in FVC of comparable magnitude evoked by infusion of the stable prostaglandin analogue, prostacyclin (PGI 2 ), nor by the NO donor, SNP (Abbas & Marshall 2000) . These ®ndings give us con®dence that diclofenac acted in a speci®c manner to inhibit the muscle vasodilatation of systemic hypoxia in that it had no effect on dilator responses that are not expected to require prostaglandin synthesis. They also suggest that blockade of prostaglandin synthesis does not interfere with the ability of NO to induce dilatation. Given that prostaglandins act by increasing cAMP in vascular smooth muscle, this argues against the possibility that the effects of diclofenac on the hypoxia-induced dilatation are due to interference with the known synergism between cGMP and cAMP (De Wit et al. 1994) .
Seen in this light, our additional ®nding that diclofenac reduced an increase in FVC equivalent in magnitude to that of systemic hypoxia, but induced by infusion of adenosine (Abbas & Marshall 2000) , is particular interesting. It suggests that at least part of the in¯uence of diclofenac on the hypoxia-induced dilatation is caused by an effect on the component of that dilatation that is mediated by adenosine. Yet, in experiments in which the adenosine receptor antagonist 8-SPT was given after diclofenac there was a further reduction in the increase in FVC evoked by hypoxia, such that only 15±20% of the original dilatation remained (Abbas & Marshall 2000) . Taken together, these results suggest that there is some interaction between the pathways by which adenosine and prostaglandins induce dilatation in hypoxia, but indicate that adenosine at least, can act independently of prostaglandins. Given the lack of effect of diclofenac on NO-evoked dilatation, it may be that the interaction occurs at the level of the endothelial cells. For example, the mechanisms that trigger the synthesis of NO and PGs may be mutually facilitatory. Certainly, there is substantial in vivo and in vitro evidence that NO can activate the cyclooxygenase enzyme that generates prostaglandins and there is evidence in rat Kupffer cells that cAMP generated by prostaglandin formation can modulate NO production (see Di-Rosa et al. 1996) .
Adenosine and sympathetic transmission
As indicated above (see Fig. 2 ), there is a further possibility that adenosine induces vasodilatation in systemic hypoxia by acting presynaptically to inhibit the release of transmitter(s) from sympathetic nerve varicosities or by acting postsynaptically to interfere with the ability of the transmitter(s) to cause vasoconstriction. This would be analogous to the`sympatholysis' of muscle contraction, the term used to describe the reduced vasoconstrictor effect of sympathetic activity that occurs in skeletal muscle during muscle contraction (see Thomas, this volume) . It may be noted that Rowell et al. (1989) have already suggested presynaptic inhibition of noradrenaline release as a possible explanation for their ®ndings that in human subjects, the muscle vasodilatation of systemic hypoxia was accompanied by a 300% increase muscle sympathetic nerve activity, but no increase in the venous ef¯ux of noradrenaline from muscle.
We know from multiunit recordings of the activity in sympathetic ®bres that are destined for skeletal muscle tissue that the activity is low under resting, normoxic conditions: the average ®ring frequency is 1± 3 Hz, but it has a strong cardiac and respiratory rhythm (Habler et al. 1994a , b, Mace®eld et al. 1994 . Similar multiunit recordings have shown that in both rat and man, systemic hypoxia causes an increase in the sympathetic activity to muscle: an increase in the frequency of bursts and frequency of pulses within bursts as might be expected from the concomitant hypoxia-induced increase in heart rate and respiration (Saito et al. 1988 , Rowell et al. 1989 , Habler et al. 1994a . Recordings made from single sympathetic ®bres in the nerve network that supplies the tail artery of the rat allows a more detailed analysis of the patterning of sympathetic activity to vascular tissue. They have shown that naturally, the sympathetic activity to arterial vessels is very irregular and can comprise periods of silence punctuated by bursts of varying lengths with instantaneous intraburst frequencies ranging from 0.03 Hz to as high as 20±50 Hz (Johnson & Gilbey 1996 8 ). Using this information as a basis, we have recently been investigating the responses that are evoked in muscle vasculature in normoxia and in systemic hypoxia. We have stimulated the lumbar sympathetic chain (LSC) with irregular activity recorded from a single ®bre on the tail artery or with patterns of activity modelled to include important characteristics of the activity that might occur in such ®bres during systemic hypoxia.
When the LSC was stimulated with a pattern of irregular activity recorded from a single sympathetic ®bre under normoxic conditions, then the evoked changes in FVR were well-correlated with the patterns of nerve activity: singlet and couplet pulses evoked small increases in FVR, while longer trains of pulses evoked larger increases in FVR that were graded in magnitude and duration to intraburst frequency and duration. These changes in FVR were greatly reduced by the adrenoreceptor antagonist phentolamine, showing they were mainly mediated by noradrenaline. However, small changes in FVR persisted that were blocked by suramin which antagonizes the P 2 purinoreceptors for ATP (Johnson et al. 1999) . This strongly suggests that a component of the vasoconstrictor responses evoked in muscle vasculature by sympathetic nerve activity is mediated by nerve-released ATP and thereby, raises the real possibility that during systemic hypoxia, sympathetically mediated vasoconstriction might be modulated by adenosine that is generated from nerve-released ATP, as well as by adenosine that is released by the endothelial cells.
To test these possibilities we have stimulated the LSC with three different patterns of pulses each delivered for 1 min and containing the same total number of pulses: a constant frequency of 2 Hz and bursts of 20 or 40 Hz repeated six times per minute. In keeping with previous reports, the bursting patterns evoked larger increases in FVR than those evoked by constant stimulation at 2 Hz (Pernow et al. 1989) . All of these responses were substantially reduced by infusion of adenosine given at a dose chosen to mimic the dilatation induced by breathing 8% O 2 . However, whereas the inhibitory effect of adenosine on the increase in FVR evoked by constant stimulation at 2 Hz was partially alleviated by the selective A 1 adenosine receptor antagonist DPCPX, the inhibitory effect of adenosine on the increases in FVR evoked by burst stimulation at 40 Hz was enhanced. The latter would be expected if DPCPX removed a facilitatory in¯uence of A 1 receptor stimulation on sympathetic vasoconstriction (Coney & Marshall 1999a ). These results can be explained if (i) adenosine not only antagonizes the vasoconstrictor effects of sympathetic activation by acting postsynaptically on A 1 receptors, but can also (ii) facilitate sympathetic transmission by acting presynaptically on A 1 receptors (Fig. 4) . The postsynaptic A 1 receptors could be on the endothelium as discussed above. Evidence for presynaptic A 1 receptors has been obtained in in vitro studies on rabbit ear artery (Maynard & Burnstock 1994) .
In full accord with these suggestions, when we applied the three different patterns of stimulation to the LSC during graded levels of systemic hypoxia, the increase in FVR evoked by constant stimulation at 2 Hz was progressively reduced by breathing 12, 10 and 8% O 2 . On the other hand, that evoked by bursting at 40 Hz was enhanced by breathing 12% O 2 and tended to be inhibited by breathing 8% O 2 , (Coney & Marshall 1999b) .
From these results, it seems that when the level of systemic hypoxia is moderate, adenosine that probably originates from the sympathetic nerve varicosities acts presynaptically on A 1 receptors to facilitate sympathetic vasoconstriction caused by high frequency bursts. This may help to overcome the inhibitory in¯uence that adenosine released from endothelial cells has on sympathetically mediated vasoconstriction, by acting on endothelial A 1 receptors to cause dilatation. However, when the level of systemic hypoxia is more severe, it seems the postsynaptic inhibitory or dilator, in¯uence of the A 1 receptors predominates, whether the sympathetic ®bres are activated at constant low frequency or with high frequency bursts. In other words, it is probable that the postsynaptic dilator in¯uence of adenosine can largely overcome any vasoconstriction that might be expected from the re¯ex increase in sympathetic activity that occurs in systemic hypoxia.
It may be noted that although there is evidence for presynaptic A 1 receptors that inhibit noradrenaline release (Concalves & Quieroz 1996) , our results do not require this mechanism. Indeed, we have no evidence that a presynaptic in¯uence of adenosine explains the lack of venous ef¯ux of noradrenaline from muscle during hypoxia-evoked increases in sympathetic nerve activity (see Rowell et al. 1989) . It may be that some other factor that is released by tissue hypoxia is responsible, for example, prostaglandins or K + , both of which are known to act presynaptically to inhibit noradrenaline release (Vanhoutte et al. 1981) .
CONCLUSION
Our results indicate that adenosine makes a major contribution to the dilatation that occurs in skeletal muscle during systemic hypoxia. We propose that when hypoxic blood perfuses the arterioles, adenosine is released from the endothelial cells or ATP is released and is dephosphorylated extracellularly to adenosine. Adenosine then acts on A 1 receptors on the endothelium to cause dilatation in a NO-dependent manner that is largely attributable to the action of newly synthesized NO (Fig. 4) . However, our new evidence that hypoxia-and adenosine-induced vasodilatation are also dependent on prostaglandin synthesis suggests that the adenosine, NO and prostaglandin dilator pathways are interdependent. We propose that such endothelium-dependent dilatation varies in magnitude in different regions of muscle, in proportion to the local level of hypoxia, and that it serves to increase the homogeneity of O 2 distribution thus allowing O 2 consumption to be maintained even when O 2 delivery is greatly reduced. By contrast, we propose that adenosine released from the skeletal muscle ®bres makes a relatively minor contribution to the hypoxia-induced dilatation. It acts on A 1 and A 2A receptors on the muscle ®bres that are coupled to K ATP channels thus causing an ef¯ux of K + ions that are vasodilators and may act directly on A 1 receptors on the vascular smooth muscle to cause dilatation. Finally, our results suggest that adenosine that originates from the ATP released as a sympathetic transmitter can facilitate the vasoconstrictor in¯uence of bursting patterns of sympathetic activity during moderate hypoxia by acting on presynaptic A 1 receptors. However, during more severe hypoxia, adenosine that is probably endothelially derived inhibits vasoconstriction evoked by constant or high frequency bursts of sympathetic activity by acting postsynaptically on the endothelial A 1 receptors. The latter effect must limit the extent to which activation of sympathetic ®bres can further reduce the O 2 supply to the tissue cells at a time when the O 2 delivery via the blood stream is already reduced.
